| 18.23 0 (0%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.08  |
1-year : | 25.79 |
| Resists | First : | 18.9 |
Second : | 22.08 |
| Pivot price | 16.82 |
|||
| Supports | First : | 15.71 |
Second : | 13.73 |
| MAs | MA(5) : | 17.77 |
MA(20) : | 16.37 |
| MA(100) : | 15.65 |
MA(250) : | 13.48 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 91.6 |
D(3) : | 87.6 |
| RSI | RSI(14): 64.4 | |||
| 52-week | High : | 18.9 | Low : | 9.52 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ELMD ] has closed below upper band by 14.9%. Bollinger Bands are 59.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.93 - 19.03 | 19.03 - 19.12 |
| Low: | 17.67 - 17.78 | 17.78 - 17.87 |
| Close: | 18.05 - 18.24 | 18.24 - 18.4 |
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Fri, 13 Sep 2024
Electromed stock soars to 52-week high, hits $18.63 - Investing.com India
Wed, 11 Sep 2024
Electromed announces stock buyback program - TradingPedia
Wed, 11 Sep 2024
Electromed, Inc. Announces Share Repurchase Authorization - StockTitan
Wed, 28 Aug 2024
Electromed, Inc. (AMEX:ELMD) Q4 2024 Earnings Call Transcript - Insider Monkey
Tue, 27 Aug 2024
Electromed Inc (ELMD) Q4 FY 2024 Earnings: EPS of $0.20 Beats Es - GuruFocus.com
Tue, 27 Aug 2024
Electromed, Inc. Announces Record Fiscal Year 2024 Financial Results - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 25 (%) |
| Held by Institutions | 34 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 38 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.44 |
| Profit Margin | 6.5 % |
| Operating Margin | 1.1 % |
| Return on Assets (ttm) | 6 % |
| Return on Equity (ttm) | 8.9 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 4.25 |
| Sales Per Share | 5.79 |
| EBITDA (p.s.) | 0.55 |
| Qtrly Earnings Growth | 89.3 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 49.27 |
| PEG Ratio | 1.8 |
| Price to Book value | 4.09 |
| Price to Sales | 3.14 |
| Price to Cash Flow | 56.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|